Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Oct;116(4):579-585.
doi: 10.1007/s12185-022-03397-7. Epub 2022 Jul 10.

Management of lymphoma-associated chylothorax by interventional radiology and chemotherapy: a report of five cases

Affiliations
Case Reports

Management of lymphoma-associated chylothorax by interventional radiology and chemotherapy: a report of five cases

Ami Fukumoto et al. Int J Hematol. 2022 Oct.

Abstract

Chylous effusion is associated with lymphatic obstruction or leakage in mediastinal or abdominal lymph nodes, and is a rare but troublesome complication in patients with malignant lymphomas. Although there is no standard of care, it is often treated with simultaneous chemotherapeutic and non-chemotherapeutic interventions. Here, we describe the cases of five patients with lymphoma-associated chylothorax with the aim of clarifying an effective treatment strategy. All patients achieved a partial response or better for lymphoma. All patients underwent interventional radiology (IVR) procedures, including lymphangiography (LAG) and thoracic duct embolization (TDE). Complete resolution of chylothorax was eventually achieved by IVR procedures or pleurodesis in all patients. No patients experienced serious adverse events related to LAG/TDE. Treatment of chylous effusion required months for most patients (range: 0.2-4.8 months). Our data suggest that a combination of chemotherapy and LAG/TDE is effective for refractory lymphoma-related chylous effusion.

Keywords: Chemotherapy; Chylous effusion; Lymphangiography; Lymphoma; Thoracic duct embolization.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Staats BA, Ellefson RD, Budahn LL, Dines DE, Prakash UB, Offord K. The lipoprotein profile of chylous and nonchylous pleural effusions. Mayo Clin Proc. 1980;55:700–4. - PubMed
    1. Doerr CH, Allen MS, Nichols FC, Ryu JH. Etiology of chylothorax in 203 patients. Mayo Clin Proc. 2005;80:867–70. - PubMed - DOI
    1. Valentine VG, Raffin TA. The management of chylothorax. Chest. 1992;102:586–91. - PubMed - DOI
    1. Nair SK, Petko M, Hayward MP. Aetiology and management of chylothorax in adults. Eur J Cardiothorac Surg. 2007;32:362–9. - PubMed - DOI
    1. Al-Zubairy SA, Al-Jazairi AS. Octreotide as a therapeutic option for management of chylothorax. Ann Pharmacother. 2003;37:679–82. - PubMed - DOI

Publication types

LinkOut - more resources